EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the recipient of a significant increase in short interest in February. As of February 12th, there was short interest totalling 350,200 shares, an increase of 38.6% from the January 28th total of 252,600 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 361,500 shares, the days-to-cover ratio is presently 1.0 days.
EYPT has been the topic of a number of analyst reports. Cowen initiated coverage on EyePoint Pharmaceuticals in a research note on Monday, March 1st. They issued an “outperform” rating and a $25.00 price target on the stock. B. Riley lifted their price target on EyePoint Pharmaceuticals from $5.00 to $8.50 and gave the company a “buy” rating in a research note on Tuesday, January 12th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of EyePoint Pharmaceuticals in a research note on Friday, January 29th. Cantor Fitzgerald started coverage on EyePoint Pharmaceuticals in a research note on Wednesday, January 27th. They issued an “overweight” rating and a $22.00 price target on the stock. Finally, Zacks Investment Research downgraded EyePoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 22nd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. EyePoint Pharmaceuticals currently has an average rating of “Buy” and an average price target of $15.30.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in shares of EyePoint Pharmaceuticals in the third quarter worth $66,000. Renaissance Technologies LLC acquired a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth $117,000. Janus Henderson Group PLC acquired a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth $136,000. Financial Advisory Service Inc. acquired a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth $100,000. Finally, Cedar Mountain Advisors LLC raised its holdings in shares of EyePoint Pharmaceuticals by 450.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 11,000 shares of the company’s stock worth $72,000 after acquiring an additional 9,000 shares during the last quarter.
EYPT opened at $9.44 on Monday. The business’s fifty day moving average is $11.98 and its two-hundred day moving average is $6.99. The company has a debt-to-equity ratio of 6.69, a quick ratio of 3.40 and a current ratio of 3.68. The company has a market cap of $257.61 million, a price-to-earnings ratio of -2.78 and a beta of 1.62. EyePoint Pharmaceuticals has a one year low of $3.51 and a one year high of $15.06.
EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, March 3rd. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of $0.45 by ($1.52). EyePoint Pharmaceuticals had a negative return on equity of 434.26% and a negative net margin of 112.23%. On average, analysts predict that EyePoint Pharmaceuticals will post -1.89 EPS for the current fiscal year.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: What is a good dividend yield?
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.